Search 

Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.

Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.

Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.

Respinova has developed a novel non-invasive technology that aims to treat the core of the COPD pathophysiology – small airway collapse.

Respinova's solution uses unique pulses of air pressure generated by a proprietary device called PulseHaler™. ​The small airways have no cartilage structural support and are totally dependent on the tethering forces of the surrounding lung. When these forces are diminished, the small airways collapse and do not permit airflow to the gas-exchanging alveolar zone of the lung. When COPD starts, airways initially reopen on inspiration. Once the disease progresses, the airways open only on deep inspiration, and finally not at all. When the small airways collapse, not only is gas exchange is impaired, but also the cilia clearing mechanism fails, and secretions accumulate to further worsen the situation.

The small airways have little or no smooth muscle in their walls so that neither beta-adrenergic nor muscarinic drugs can open them up, even if the particles manage to be delivered to the small airways.

The PulseHaler™ generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, thereby creating multiple momentary dilating forces that help gently pry open the collapsed airways. PulseHaler™ also generates positive pressure on exhalation, which helps with airway opening. The pulses also help in smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.

Santen Pharmaceutical Co., Ltd. (参天製薬株式会社), is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.

We are looking for investment and licensing opportunites in the ophthalmology field.